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Abstract 
Childhood bone cancer though rare, has very limited treatment choices with poor survival 
rates and often involving amputation. We have developed a novel molecule, 2', 4'-
dihydroxydithiondibenzoylmethane and tested it in hepatic, colon, lung and osteoblasts 
cancer cell lines. Thionylation of 2', 4'-dihydroxydibenzoylmethane has  selectively targeted 
bone cancer cells, stopping the growth and leading to the death of those cancerous cells  
without affecting non-cancerous cells within the bone marrow or non-malignant cells.  
 
Introduction 
Cancer in the bones can be either primary (initiated in the bones) or secondary (has spread to 
the bones)in nature. In primary bone cancer, osteosarcoma can affect any bone in the 
skeleton, though the femurs, tibia and humerus (arms and legs) are most commonly affected. 
Osteosarcoma accounts for about 3% of  cancer in children, especially during early 
adolescence when bone growth is at its peak [1]. Ewing’s sarcoma affects mainly teenagers 
and has an incidence of 34% of bone cancers. It appears mainly in the pelvis, thigh and shin 
areas, though this type of tumour can also occur in soft tissues (soft tissue sarcomas)[2]. Rare 
forms of bone cancer account for the remaining 6% of children with bone cancer [3].  Other 
primary bone cancers that affect mainly adults over 40 years old, are chrondrosarcoma in hips, 
legs, arms and shoulders; several variations of spindle cell sarcoma; and chordoma in lungs, 
nearby bones, lymph nodes, liver and skin. Secondary cancers can arise from primary tumours 
spreading to other tissues and the most prevalent tumours resulting from secondary bone 
cancer are prostate, breast, lung, kidney and thyroid. 
As with any type of cancer, bone cancer can also be assessed in stages. For example, stage GX 
(also called stage 0) cannot be diagnosed, while low grade tumours will be divided in stages 1 
and 2 and high grade tumours will be 3 and 4 [4]. Survival rate after treatment depends highly 
on a patient’s age at the time of diagnosis, stage of the bone cancer and type of bone cancer. 
In teenagers with Ewing’s sarcoma, survival rate after treatment ranges from 20 to 70% over 
5 years but and is dependent on the site and size of the tumour [5-8].  
Treatment generally involves some type of surgery, and the stage of the cancer will determine 
which type of surgery will be used. It can vary from removing only the area affected in the 
bone to amputation of the limb. Further treatment can include radiotherapy and 
chemotherapy [9-11]. Osteosarcomas can be treated with doxorubicin (a DNA intercalator), 
methotrexate (an antimetabolite) and cisplatin (a DNA alkylator). Ewing’s sarcoma requires a 
mixture of drugs, including cocktail 1 consisting of vincristine (anti-mitotic agent), ifosfamide 
(DNA alkylator), doxorubicin, etoposide (Topoisomerase II inhibitor). This is followed by 
cocktail 2 made up of vincristine, ifosfamide and actinomycin D (DNA groove binder) and/or 
cocktail 3, which is a mixture of vincristine, actinomycin D and cyclophosphamide (DNA 
alkylator). Treatment of bone cancer with small molecules can be effective depending on the 
type of cancer and stage. However, there are side effects which affect the outcome for the 
patient. This can affect the rate of remission, produce delays in recovery times or cause long 
term effects such as fertility problems [12-17]. Biological therapies are currently being 
evaluated in clinical trials, with the aim to identify new molecules (generally antibodies or 
adjuvants) to encourage the immune system to attack the cancer cells by recruiting immune-
modulators such as TNF (tumour necrosis factors) and INF (interferons)[18, 19].  
 
Dibenzoyl-methane derivatives (DBMD) (structure 1) have been found in tea genera and have 
been used in traditional medicine to treat several conditions, ranging from infection to 
rheumatic diseases, and as antioxidants. Their biological activity has not been completely 
elucidated but studies in other cell lines indicate activities in p53, Rb (retinoblastoma), and 
mitochondria [20-23]. 
 
Structure 1: dibenzoyl-methane. 
 
Generation of DBMD derivatives 
We have employed the improved Baker-Venkatarman arrangement (Ares, Ragazzon) [25],  
 (Scheme 1) to produce five dibenzoyl-methane derivatives: 2’,4’-dihydroxy-dibenzoyl-
methane (1), 2’-hydroxy-4’-amino-dibenzoyl-methane (2) , 3’,4’,’-trimethoxy-dibenzoyl-
methane (3) , 2’,4’-dihydroxy-3’’-methoxy-dibenzoyl-methane (4), and 2’,4’-dihydroxy-4’’-
methoxy-dibenzoyl-methane (5). 
 
Scheme 1: DBMD scaffold formation by reacting different analogues of 2-
hydroxyacetophenone with benzoyl chloride and addition of potassium tert-butoxide.  
 
Thionylation of 2’,4’-dihydroxy-dibenzoyl-methane produced 2’,4’-dihydroxy-dithio-
dibenzoyl-methane (6),  (Scheme 2). 
 
Scheme 2: Thionylation of 2’,4’-dihydroxy-dibenzoyl-methane using the Lawesson’s reagent. 
 
This paper describes the development a novel molecule, 2', 4'-
dihydroxydithiondibenzoylmethane and derivatives thereof and highly promising results 
obtained in applying it against hepatic, colon, lung and osteoblasts cancer cell lines. 
 
 
Materials and methods 
A combination of compounds were obtained from various suppliers, e.g. Alfa Aesar UK: 3', 4', 
5'-Trimethoxyacetophenone, benzoyl chloride, 3-Methoxybenzoyl chloride, Lawesson's 
Reagent. TCI Tokyio Kasei: 2', 4' –Dihydroxyacetophenone, 4-Methoxybenzoyl chloride. 
Fluorochem: Potassium tert-butoxide and Silica gel (60 Å). Thermo Fisher Scientific: 4-Amino-
2-hydroxyacetophenone, dry tetrahydrofuran, hydrochloric acid, toluene, ethyl acetate, 
petroleum ether, ethanol, hexane, dimethylsulfoxide, fetal bovine serum (GIBCO), RPMI-1640 
(HyClone), 0.05% Trypsin-EDTA (GIBCO), sterile  phosphate buffered saline. VWR UK: TLC Silica 
gel 60 F245 (Merck). Cambridge isotope laboratories: deuterated chloroform. Sigma-Aldrich: 
L-Glutamine 100x, MEM Non-Essential Amino acid 100x, penicillin-streptomycin 100x, 
chlorpromazine hydrochloride,  MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium 
bromide) and Saos-2 cell line. University of Salford Cell Bank: HCT116 and A549 cell lines. 
Cyprotex: HepG2 cell line. 
 
Synthesis of 2', 4'-dihydroxydibenzoylmethane (1) 
2', 4'-dihydroxyacetophenone (1.0g, 6.57mmol) was dissolved in dry THF (tetrahydrofuran) 
(20ml) under argon added dropwise to a cooled mixture (0 ͦC) of KOtBu (1.6equiv, 1.18g) in dry 
THF (50ml) under argon. The resulting white solution was left to stir at room temperature for 
1 hour. The reaction mixture was then re-cooled to (0 ͦC) before benzoyl chloride (1equiv, 
0.762ml) was added dropwise, and the mixture was left to stir at room temperature for further 
1 hour. The reaction mixture was cooled to (0 ͦC) before KOtBu (1.6equiv, 1.18g) was added, 
and then the mixture was left to stir at room temperature for 15 min. Thereafter it was 
refluxed overnight with stirring. After 24h, TLC showed the presence of the product. The 
reaction mixture was then left to cool, and  acidified water was added slowly until a light 
yellow precipitate was formed. The precipitate was  separated by a Buchner funnel and left to 
dry for 5 min and then crystallized with ethanol to yield yellow needles. The TLC and NMR 
analysis showed the presence of starting materials, so  further purification was required. 
Column chromatography using hexane: ethylacetate as eluent was carried out to purify the 
product and produced a pure solid. Yield: 51.2%. Yellow solid. Melting point: 158 ͦC to 161 ͦC. 
1H NMR (CDCl3, ppm) δ 4.6 (s, 1H, H6'), δ 6.8 (s, 1H, H6), δ 3.4 (s, 1H, H10),    δ 6.9-8.3 (m, 8H, 
Ar-H), δ 11.7 (s, 1H, H8'), δ 12.4(s, 1H, H8), 15.5(s, 1H, H7). IR (cm-1) 1741.42cm-1 (C=O), 
3060.88CM-1( ̶OH stretch), MS m/z (relative intensity) 255.06(M-1). 13C NMR (CDCl3, ppm): 
δ 102.79 (C1), δ 158.05 (C2), δ 98.73(C3), δ 125.56(C4), δ 159.74(C5), δ 101.3(C6), δ 
197.66(C7), δ 63.22(C8), δ 189.22(C9), δ 127.58(C10), δ 126.87(C11), δ 125.84(C12), δ 
123.66(C13), δ 121.42(C14), δ 121.18(C15). 
Synthesis of 2'-hydroxy-4'-aminodibenzoylmethane  (2) 
2-hydroxy-4-Aminodibenzoylmethane (0.2g, 1.32mmol) was dissolved in dry THF 
(tetrahydrofuran) (8ml) under argon and added dropwise to a cooled mixture (0 ͦC) of KOtBu 
(1.6equiv, 0.24g) in dry THF (15ml) under argon. The resulting strong yellowish solution was 
left to stir at room temperature for 1 hour. The reaction mixture was then re-cooled to (0 ͦC) 
before benzoyl chloride (1equiv, 0.154ml) was added dropwise, and the mixture was left to 
stir at room temperature for further 1 hour. The reaction mixture was cooled to (0 ͦC) before 
KOtBu (1.6equiv, 0.24g) was added and the mixture was left to stir at room temperature for 
15 min. It was subsequently refluxed overnight with stirring. After 24h, TLC showed the 
presence of the product. The reaction mixture was then left to cool, and acidified water was 
added slowly until a brown yellowish precipitate was formed. The precipitate was  separated 
by Buchner funnel and left to dry for 5 min before being crystallized with ethanol to yield 
yellow needles. The TLC and NMR analysis showed the presence of starting materials, so  
further purification was required. Column chromatography using petroleum ether: 
ethylacetate as eluent was carried out to purify the product and produced a pure solid. Yield: 
46.3%. Yellow solid. Melting point: 110 ͦC to 112 ͦC. 1H NMR (CDCl3, ppm) δ 4.6 (s, 1H, H6'), 
δ 6.8 (s, 1H, H6), δ 5.3 (s, 2H, H10), δ 6.9-8.2 (m, 8H, Ar-H), δ 11.8 (s, 1H, H8'), δ 12.4(s, 1H, 
H8), 15.5(s, 1H, H7). IR (cm-1) 3496.3-3370.2cm-1 N ̶ H stretch (primary amine), 1602.39 
(C=O), MS m/z (relative intensity) 254.08 (M-1). 13C NMR (CDCl3, ppm): δ 92.13 (C1), δ 
163.83(C2), δ 108.14(C3), δ 134.38(C4), δ 163.88(C5), δ 115.44(C6), δ 194.45(C7), δ 26.41(C8), 
δ 176.87(C9), δ 144.66(C10), δ 133.68(C11), δ 132.13(C12), δ 129.92(C13), δ 128.50(C14), δ 
127.14(C15). 
 
Synthesis of 3', 4', 5'-trimethoxydibenzoylmethane (3) 
3', 4', 5'-Trimethoxyacetophenone (1g, 4.76mmol) was dissolved in dry THF (tetrahydrofuran) 
(20ml) under argon and added dropwise to a cooled mixture (0 ͦC) of KOtBu (1.6equiv, 0.85g) 
in dry THF (50ml) under argon. The resulting brown yellowish solution was left to stir at room 
temperature for 1 hour. The reaction mixture was re-cooled to (0 ͦC) before benzoyl chloride 
(1equiv, 0.55ml) was added dropwise, and the mixture was left to stir at room temperature 
for further 1 hour. The reaction mixture was cooled to (0 ͦC) before KOtBu (1.6equiv, 0.85g)  
was added and the mixture was left to stir at room temperature for 15 min. It was then left to 
reflux overnight with stirring. After 24h, TLC showed the presence of the product. The reaction 
mixture was then left to cool, and  acidified water was added slowly until yellow precipitate 
was formed. The precipitate was  separated by a Buchner funnel and left to dry for 5 min and 
then crystallized with ethanol to yield yellow needles. The TLC and NMR analysis showed the 
presence of starting materials, so  further purification was required. Column chromatography 
using hexane: ethyl acetate as eluent was carried out to purify the product and produced a 
pure solid. Yield: 51.0%. Brown solid. Melting point: 99 ͦC to 102 ͦC. 1H NMR (CDCl3, ppm) δ 
4.6 (s, 1H, H6'), δ 6.8 (s, 1H, H6), δ 3.9 (s, 9H, H9), 6.95-8.2 (m, 7H, Ar-H). IR (cm-1) 
2834.71cm-1 (̶ OH stretch), 1583.56(C=O), MS m/z (relative intensity) 313.10 (M-1). 13C NMR 
(CDCl3, ppm): δ 152.88 (C1), δ 142.67 (C2), (C3), (C4), δ 106.36(C5), (C6), δ 193.54(C7), δ 
64.90(C8), δ 12.16(C9), δ 134.45(C10), δ 134.08(C11), δ 130.48(C12), δ 129.01(C13), δ 
128.06(C14), (C15), δ 60.18(C-CH3O) δ 50.04(C-CH3O) δ ??(C-CH3O). 
 
Synthesis of 2', 4'-dihydroxy-3''- methoxydibenzoylmethane (4) 
2', 4' –Dihydroxyacetophenone (1.0g, 6.57mmol) was dissolved in dry THF (tetrahydrofuran) 
(20ml) under argon and added dropwise to a cooled mixture (0 ͦC) of KOtBu (1.6equiv, 1.18g) 
in dry THF (50ml) under argon. The resulting white solution was left to stir at room 
temperature for 1 hour. The reaction mixture was re-cooled to (0 ͦC) before 3-Methoxybenzoyl 
chloride (1equiv, 0.923ml) was added dropwise, and the mixture was left to stir at room 
temperature for further 1 hour. The reaction mixture was cooled to (0 ͦC) before KOtBu 
(1.6equiv, 1.18g) was added and the mixture was left to stir at room temperature for 15 min. 
It was then left to reflux overnight with stirring. After 24h, TLC showed the presence of the 
product. The reaction mixture was then left to cool, and  acidified water was added slowly 
until light yellow precipitate was formed. The precipitate was  separated by a Buchner funnel 
and left to dry for 5 min before being crystallized with ethanol to yield yellow needles. The 
TLC and NMR analysis showed the presence of starting materials, so  further purification was 
required. Column chromatography using petroleum ether: ethylacetate as eluent was carried 
out to purify the product and afford a pure solid. Yield: 47.1%. Yellow solid. Melting point: 
110 ͦC to 112 ͦC. 1H NMR (CDCl3, ppm) δ 4.6 (s, 1H, H6'), δ 6.8 (s, 1H, H6), δ 3.5 (s, 1H, 
H10), δ 3.9 (s, 3H, H2) 6.9-8 (m, 7H, Ar-H), δ 11.8 (s, 1H, H8'), δ 12.4(s, 1H, H8), 15.5(s, 1H, 
H7). IR (cm-1) 2834.71cm-1(̶ OH stretch), 1583.56(C=O), MS m/z (relative intensity) 285.07 
(M-1). 13C NMR (CDCl3, ppm): δ 113.15 (C1), δ 163.96 (C2), (C3), δ 113.15(C4), δ 164.22(C5), 
δ 119.21(C6), δ 194.72(C7), δ 92.50(C8), δ 177.36(C9), δ 134.92(C10), δ 120.51(C11), δ 
119.21(C12), δ 114.55(C13), δ 129.75(C14), δ 130.24(C15), δ 55.53(C-CH3O). 
 
Synthesis of 2', 4'-dihydroxy-4''-methoxydibenzoylmethane (5) 
2', 4' –Dihydroxyacetophenone (1.0g, 6.57mmol) was dissolved in dry THF (tetrahydrofuran) 
(20ml) under argon and added dropwise to a cooled mixture (0 ͦC) of KOtBu (1.6equiv, 1.18g) 
in dry THF (50ml) under argon. The resulting white solution was left to stir at room 
temperature for 1 hour. The reaction mixture was re-cooled to (0 ͦC) before 4-metoxybenzoyl 
chloride (1equiv, 0.89ml) was added dropwise, and the mixture was left to stir at room 
temperature for further 1 hour. The mixture was cooled to (0 ͦC) before KOtBu (1.6equiv, 1.18g) 
and then was left to stir at room temperature for 15. It was left to reflux overnight with 
stirring. After 24h, TLC showed the presence of product. The reaction mixture was then left to 
cool, and  acidified water was added slowly until a light yellow precipitate was formed. The 
precipitate was  separated by a Buchner funnel,  left to dry for 5 min and then crystallized with 
ethanol to yield yellow needles. The TLC and NMR analysis showed the presence of starting 
materials, so  further purification was required. Column chromatography using hexane: 
ethylacetate as eluent was carried out to purify the product and produced a pure solid. Yield: 
51.3%. Yellow solid. Melting point: 137 ͦC to 141 ͦC. 1H NMR (CDCl3, ppm) δ 4.6 (s, 1H, H6'), 
δ 6.75 (s, 1H, H6), δ 3.5 (s, 1H, H10), δ 3.9 (s, 3H, H3) 6.8-8.3 (m, 7H, Ar-H), δ 11.8 (s, 1H, 
H8'), δ 12.4(s, 1H, H8), 15.5(s, 1H, H7). IR (cm-1) 3475.03cm-1 (̶ OH stretch), 1606.08(C=O), 
MS m/z (relative intensity): 285.07 (M-1). 1C NMR (CDCl3, ppm): δ 102.24 (C1), δ 164.16 (C2), 
δ 108.07(C3), δ 133.69(C4), δ 166.96(C5), δ 113.77(C6), δ 202.68(C7), δ 55.40(C8), δ ??(C9), δ 
122.91(C10), δ 131.30(C11), δ 112.82(C12), δ 26.33(C-CH3O). 
 
Synthesis of 2', 4'-dihydroxydithiondibenzoylmethane: thionylation of the carbonyl groups 
of 2', 4'-dihydroxydibenzoylmethane (6) 
Lawesson’s reagent (0.6equiv) was added to Benzoyl-(2', 4'-dihydroxy benzoyl)-methane (0.5g, 
1.95mmol) which was dissolved in toluene (25ml). The reaction was then refluxed with stirring 
overnight. After 24h TLC showed the presence of the product. The solvent was then 
evaporated and the residue purified by preparative TLC using petroleum ether: ethylacetate 
as eluent to yield a red solid. Yield: 60.7%. Red solid. Melting point: 165 ͦC to 167 ͦC. 1H NMR 
(CDCl3, TMS, ppm) δ 3.3 (s, 1H, H6'), δ 5.3 (s, 2H, H10), δ 6.9-8.5 (m, 8H, Ar-H). IR (cm-1) 
3246.42cm-1(̶ OH stretch), 3065.79cm-1 (C ̶ H stretch), MS m/z (relative intensity): 575.07 
(2M-1). 1C NMR (CDCl3, ppm): δ 102.79 (C1), δ 158.05 (C2), δ 98.73(C3), δ 125.56(C4), δ 
159.74(C5), δ 101.3(C6), δ 197.66(C7), δ 63.22(C8), δ 189.22(C9), δ 127.58(C10), δ 
126.87(C11), δ 125.84(C12), δ 123.66(C13), δ 121.42(C14), δ 121.18(C15). 
 
Cell maintenance: 
Cells were grown as adherent monolayer culture in 75cm2 flasks in RPMI 1640 medium 
supplemented with 10% heat inactivated fetal bovine serum (FBS), 1% v/v nonessential amino 
acids (NEAA), 2mM L-glutamine and 115 units/mL of penicillin G, and 115 μg/mL of 
streptomycin at 37 °C under a humidified atmosphere containing 5% CO2 and 95% air.  
MTT and IC50 determination: 
The six compounds were tested at a range of concentrations (range, 0-100 μM) and cell death 
percentage was determined by the colorimetric MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide] micro-culture assay. Cells were detached from the 75cm2 
flasks (at a confluence of 70%) by trypsinisation, seeded in 100μL aliquots into 96-well clear 
micro-culture plates. Cell densities of 3.0 × 103 cells/well for 72 hours of incubation was 
chosen in order to ensure exponential growth of untreated controls throughout the 
experiment. Cells were allowed to adhere into the 96-well micro-culture plate for 24 hours 
prior to dosing. Stock solutions of the test compounds in DMSO were appropriately diluted in 
complete culture media to make up the required concentrations, and then added in 25μL 
aliquots into the 96-well micro-culture plate. Cells were exposed to the test compounds for 
72 hours. Plates were maintained at 37°C in a humidified atmosphere containing 95% air and 
5% CO2. At the end of the incubation period, 30μL/well MTT solution in phosphate-buffer 
(PBS) (3 mg/mL) were added, and then incubated for further 3 hours. After the end of the 
incubation, the supernatants containing the medium and MTT were removed and the 
formazan crystals formed by viable cells were dissolved in 100μL of DMSO per well. Optical 
densities at λ = 540 nm were measured with LUMIistar Omega multi-mode plate reader. The 
colorimetric MTT assay was used to determine the cell death percentage at serial diluted 
concentrations of the tested compounds and the IC50 (the concentration at which 50% of cell 
growth was inhibited as compared to the control wells which did not contain any drug) was 
determined from a dose response curve using OriginPro 9.1 data analysis and graphing 
software. 
Caspase assay: 
2', 4'-dihydroxydithiondibenzoylmethane was tested at a range of concentrations (range, 0-5-
10 and 20 μM) and caspase activity was determined by using an ApotoxGlo® (Promega) assay. 
Cells were detached from the 75cm2 flasks (at a confluence of 70%) by trypsinisation, and 
seeded in 100μL aliquots into 96-well clear micro-culture plates. Cell densities of 5, 4 and 3.0 
× 103 cells/well were incubated for 24, 48 and 72 hours, respectively. Cells were allowed to 
adhere to the 96-well micro-culture plate for 24 hours prior to dosing. Stock solutions of the 
test compounds in DMSO were appropriately diluted in complete culture media to make up 
the required concentrations, and then added in 25μL aliquots into the 96-well micro-culture 
plates. Cells were exposed to the test compounds for 24, 48 and 72 hours. Plates were 
maintained at 37°C in a humidified atmosphere containing 95% air and 5% CO2. At the end of 
the incubation period 20μL/well of the part 1 ApotoxGlo® was added and after 30 minutes of 
incubation at 37ºC cell viability was read at 404 excitation / 520 emission with LUMIistar 
Omega multi-mode plate reader. Caspase assay was performed by adding part 2 of the 
ApotoxGlo® as 100μL/well and incubating for 30 minutes at room temperature. The 
luminescence was read using the same plate reader in luminescence mode. The data was 
analysed and normalised. 
 
Results: 
 
Chemical synthesis. 
A new family of dibenzoyl-methane derivatives were synthesised employing the Baker-
Venkatarman rearrangement of acetophenones with benzoyl chloride in the presence of 
potassium tert-butoxide.  The 2-acetoxyacetophenones reacted in a straightforward manner 
with benzoyl chloride in the presence of KOtBu (acting as the condensing agent) via the 
formation of enolate, followed by the acyl transfer as shown in scheme 2: 
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Scheme 2: Elucidation of the reaction mechanism of the synthesis of dibenzoylmethane 
derivatives. 
 
To obtain  thionylated derivatives that could provide different characteristics, we synthesised 
2', 4'-dihydroxydithiodibenzoylmethane, by reacting the benzoylmethane with the Lawesson’s 
reagent as shown in scheme 3.  
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Scheme 3: Schematic elucidation of the reaction mechanism of the synthesis of 2', 4'-
dihydroxydithiodibenzoylmethane. 
 
The reactions proceeded without any problem, and compounds were purified using flash 
chromatography and then fully characterised (Accurae MS, NMR and IR). The two carbonyl 
oxygens on the dibenzoyl-methane derivatives are known to form hydrogen bonding. This was 
observed in the proton NMR at higher than 10ppm. 
 
Biological activity 
Saos-2 (Sarcoma osteogenic) is a bone cancer cell line derived from the primary osteosarcoma 
of an 11-year-old Caucasian girl. This cancer cell line possesses several osteoblastic features 
that makes it extremely useful as a permanent line of human osteoblast-like cells for drug 
discovery and as a source of bone-related molecules [24].  
We tested all six compounds on HepG2 (children liver cancer), HCT116 (adult colon cancer), 
A549 (adult lung cancer) and Saos2 (children osteoclast) cell lines for 72 hours (Table 1). 
2’,4’-dihydroxybenzoylmethane (1), 3’,4’, 5’-trimethoxybenzoylmethane (3) and 2’,4’-
dihydroxy – 3’’ methoxy benzoylmethane (4) showed similar activity on all the cell lines with 
4-10 (μM) for IC50 at 72 hours of incubation. The amino substituent in 2’- hydroxyl-4’-
aminobenzoylmethane (2) produced loss of activity by a factor of 5 times on HepG2, HCT116 
and A549 with near 20 (μM) for IC50 at 72 hours of incubation. However, it showed a clear 
preference for Saos-2. From this group with hydroxyl and methoxy substitutions, 2’,4’-
dihydroxy – 4’’ methoxy benzoylmethane (4)  presented high activity at around 4 (μM) for 
IC50 at 72 hours of incubation, but no selectivity on the cell lines.  
From our six compounds, the tyonilated 1-(2', 4'-dihydroxyphenyl)-3-phenyl-propane-1, 3-
dithion (6) showed  poor activity on HepG2 and A549 (IC50 of 33.43 and 43.54 μM 
respectively), moderate activity on HCT116 (IC50 of 13.17 43.54 μM) and a strong selection 
and activity on Saos-2 (IC50 of 4.33 μM). We observed this compound was between 3 and 10 
times more selective for the children osteoclast cell line.  
 
Table 1: IC50 of DBM derivatives against HepG2, HCT116, A549 and SAOS-2 human 
cancer cells after 72h. 
 
Compound 
Inhibitory concentration, IC50 (μM) / 72h 
HepG2  cell line HCT116 cell 
line 
A549  cell 
line  
Saos-2 cell line 
2', 4'-dihydroxydibenzoylmethane (1) 
 
4.88 ± 1.19 5.32 ± 0.70 4.68 ± 0.88 6.49 ± 0.83 
2'-hydroxy-4'-
aminodibenzoylmethane(2) 
 
19.69 ± 0.83 13.90 ± 2.95 18.30 ± 30 5.44 ± 1.18 
3',4',5'-trimethoxydibenzoylmethane (3) 
 
3.92 ± 0.45 5.35 ± 0.47 4.25 ± 0.65 6.73 ± 0.55 
2', 4'-dihydroxy-3''-
methoxydibenzoylmethane (4) 
 
 
9.31 ± 1.34 5.55 ± 0.65 6.61 ± 0.56 3.95 ± 0.46 
2', 4'-dihydroxy-4''-
methoxydibenzoylmethane (5) 
 
3.96 ± 1.04 2.82 ± 0.86 2.83 ± 0.47 3.56 ± 0.27 
1-(2', 4'-dihydroxyphenyl)-3-phenyl-
propane-1, 3-dithion (6) 
 
33.43 ± 2.88 13.17 ± 0.72 43.54 ± 3.13 4.33 ± 0.64 
Chlorpromazine hydrochloride (CPZ) 
Positive control 
7.62 ± 0.67 7.89 ± 1.00 10.84 ± 1.54 5.07 ± 0.7 
 
Apoptosis is a form of programmed cell death and is caspase dependant, which is a safe guard 
mechanism protecting the organism while sacrificing the individual cell, 
(http://cshperspectives.cshlp.org/content/5/6/a008672.full). Some drugs, such as 
doxorubicin and dactinomycin, are activators of the caspase pathway 
(http://pubs.acs.org/doi/abs/10.1021/mp070002r). However, other pathways of cell death 
are also possible in which caspases are not activated., These can include: autophagy, 
paraptosis, mitotic catastrophe, and the descriptive model of apoptosis-like and necrosis 
(http://clincancerres.aacrjournals.org/content/11/9/3155.abstract), 
(http://www.ncbi.nlm.nih.gov/books/NBK6197/). Drugs with cytotoxic properties can trigger 
necrosis as a death stimuli, with features such as disrupted cell membrane, destruction of 
organelles, swelling and then shrinking of the cell and with the toxic waste being dispersed 
within the surrounding cells (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4075070/), 
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867948/). These caspase independent 
mechanisms can be produced by reactive oxygen species produced by an external stimuli in 
the mitochondria (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3823134/). This 
mechanism can be activated by molecules interacting with the T cell / interferon / Toll-like / 
TNF superfamily receptors (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4343053/) and 
various anticancer molecules  such as ionomycin 
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1905487/), and catechins from green tea, 
(http://onlinelibrary.wiley.com/doi/10.1111/j.1349-7006.2008.01046.x/full). In a bid to 
identify a mode of action, we employed the ApoToxGlo® (Promega) assay for assessing the 
mode of action. The caspase assay is composed of a substrate (proluminescent caspase-3/7 
DEVD-aminoluciferin) which is cleaved and the free aminoluciferin is reacted by the luciferase, 
producing a luminescent signal proportional to the caspase-3/7 activity. 
(http://www.promega.com/~/media/Files/Resources/Protocols/Technical%20Manuals/101/
ApoTox-Glo%20Triplex%20Assay%20Protocol.pdf). We tested 1-(2', 4'-dihydroxyphenyl)-3-
phenyl-propane-1, 3-dithion (6) at 5, 10 and 20 µM for 24, 48 and 72 hours and normalised 
the data to the vehicle control dimethylsulfoxide. The results indicate 1-(2', 4'-
dihydroxyphenyl)-3-phenyl-propane-1, 3-dithion (6) decreased the caspase activity steadily as 
the concentration was increased (see Table 2). At an exposure of 24 hours the caspase activity 
was reduced between 30-40 %, at 48 hours it was reduced around 50% and for a longer 
exposure of 72 hours the activity was similar to the 1 day exposure as the level of activity was 
around 60%. 
 
 Table 2: Caspase activity for 1-(2', 4'-dihydroxyphenyl)-3-phenyl-propane-1, 3-dithion. 
 
Compound (μM) 
Caspase activity, normalised to DMSO / Saos-2 cell line 
24 hours 48 hours 72 hours 
5 77.21 ± 0.35 49.85 ±2.91 66.58 ± 30.83 
10 69.07 ± 4.27 48.32 ± 5.37 61.26 ± 6.90 
20 59.23 ± 15.15 40.54 ± 11.16 53.40 ± 0.71 
 
From the caspase studies we can assume the mode of action is related to primary necrosis, 
characterised by caspase independent death, loss of proliferation, membrane 
permeabilisation and cell shrinkage amongst some of the features 
(http://www.nature.com/onc/journal/v27/n50/pdf/onc2008311a.pdf).  
 
Conclusion 
Treating cancer in children aggressively is the best option for continued health, despite the 
risk that side effects can arise  years later. Sometimes sequels from surgery can also diminish  
quality of life afterwards. Producing new selective and effective anticancer agents has become 
a goal for  many labs which are now focusing their resources in this direction to achieve that 
aim.  
Nature has provided us with some of the best anticancer drugs, so one can take this as an 
indication of where to focus attention in the quest for new drugs to treat cancer. In this paper 
we used classic organic reactions to produce a family of dibenzoyl-methane derivatives with 
promising anti-cancer activities. Using established organic methods, we produced 6 
compounds that were tested for anticancer activity on different cell lines including hepatic, 
colon, lung and osteoblast cancers. Though all compounds showed some degree of activity 
against the cancer cell lines, 1-(2', 4'-dihydroxyphenyl)-3-phenyl-propane-1, 3-dithion (6) 
produced the most promising and interesting results. This novel compound, tested on 
different types of cancer cells, has shown to be very selective for the osteoblasts, something 
that could lead  to the deduction that this compound would produce less side effects related 
to gastro-intestinal problems. This property can be exploited in formulation studies, as well as 
following it up for chemical modifications to produce a subsequent family of dithionated 
dibenzoyl-methane compounds. We concluded that primary necrosis is the mode of action 
responsible for the successful action against cancer cells.. 
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